[Endocrine therapy of breast cancer].
A survey is given about the value of endocrine especially adjuvant treatment of breast cancer, the necessary case selection procedure with aid of time- and therapy dependent hormonal receptor status using new introduced monoclonal antibodies and of the practical possibilities. Special attention was directed to the very potent substances with less side effects aminoglutethimide, tamoxifen and high dose medroxyprogesteronacetate.
D000616:Aminoglutethimide / Q000627:therapeutic use; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D011960:Receptors, Estrogen / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects; D013629:Tamoxifen / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D006728:Hormones; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D000616:Aminoglutethimide; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Endokrine Therapie des Mammakarzinoms.